Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A global, randomized registration-enabling Phase 3 trial of avapritinib versus sunitinib in patients with PDGFRA- and KIT-driven second-line advanced GIST who do not have the KIT V654A or T670I mutations

Next Previous
Trial Profile

A global, randomized registration-enabling Phase 3 trial of avapritinib versus sunitinib in patients with PDGFRA- and KIT-driven second-line advanced GIST who do not have the KIT V654A or T670I mutations

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 06 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avapritinib (Primary) ; Sunitinib
  • Indications Gastrointestinal stromal tumours
  • Focus Registrational; Therapeutic Use
  • Acronyms COMPASS-2L
  • Sponsors Blueprint Medicines

    • Most Recent Events

    • 28 Oct 2019 According to a Blueprint Medicines media release, the company plans to prioritize completion of the VOYAGER trial and delay initiation of this (COMPASS-2L) trial in second-line GIST.
    • 01 Aug 2019 According to a Blueprint Medicines media release, this trial is expected to be initaiated by the end of 2019.
    • 27 Mar 2019 According to a Blueprint Medicines media release, this trial is one of the trials which will be funded by the net proceeds of the public offering announced today by the company.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top